Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Simon Read
AddedMar 31, 2024
UpdatedMay 31, 2026
Simon Read

Simon Read

Founder & CEO, Curie Therapeutics

CrunchbaseLinkedIn

Simon Read's Career

Curie Therapeutics
Curie Therapeutics

Boston, MA, US

Founder & CEO· C-Suite · Management
Triana Biomedicines
Triana Biomedicines

Waltham, MA, US

Board Member· Board
Q32 Bio
Q32 Bio

Waltham, MA, US

Board Member· Board
Mariana Oncology
Mariana Oncology

Watertown, MA, US

Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Simon Read's Career

Curie Therapeutics
Curie Therapeutics
Acquired$75M02020Boston, MA, US
Founder & CEO· C-Suite · Management

Leadership at Curie Therapeutics

Kevin BittermanKevin BittermanBoard Member
Kapil DhingraKapil DhingraBoard Member
Triana Biomedicines
Triana Biomedicines
Series A$160.8M372019Waltham, MA, US
Board Member· Board

Leadership at Triana Biomedicines

Chris O’DonnellChris O’DonnellBoard Member
Q32 Bio
Q32 Bio
Series B$106M442017Waltham, MA, US
Board Member· Board

Leadership at Q32 Bio

Shelia VioletteShelia VioletteCo-Founder
Jodie MorrisonJodie MorrisonCEO
Mark IwickiMark IwickiBoard Member
Dave GrayzelDave GrayzelCo-Founder
Mariana Oncology
Mariana Oncology
Series B$250M322021Watertown, MA, US
Founder & CEO· C-Suite · Management

Leadership at Mariana Oncology

Rebecca LuseRebecca LuseBoard Member
Geert-Jan MulderGeert-Jan MulderBoard Member

Similar to Mariana Oncology

Radionetics OncologyRadionetics OncologySan Diego, CA, USRadiopharmaceuticalsest. 2021Radionetics OncologySan Diego, CA, US · est. 2021

Radionetics Oncology: Innovating novel radiotherapeutics for diverse oncology treatments.

Series A · $82.5M20
Aktis OncologyAktis OncologyBoston, MA, USRadiopharmaceuticalsest. 2021Aktis OncologyBoston, MA, US · est. 2021

Aktis Oncology: Biotech pioneer in developing targeted radiopharmaceuticals for solid tumors.

Series A · $156M43
Illumina RadiopharmaceuticalsIllumina RadiopharmaceuticalsNew York City, NY, USRadiopharmaceuticalsest. 2019Illumina RadiopharmaceuticalsNew York City, NY, US · est. 2019

Illumina Radiopharmaceuticals, a NYC-based organization founded in 2019.

Angel · $250k6

Simon Read's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Simon Read

Joe CostelloJoe CostelloBoard Member · KwikbitKeval RajKeval RajCo-Founder · QuickllySean FriedlandSean FriedlandCo-Founder · Trust.Mike MathiaMike MathiaBoard Member · KnoxxJohn DiGennaroJohn DiGennaroCo-Founder · QwicklyAdrian BialonczykAdrian BialonczykFounder · Algo Depth